Cooperative Agreement U01CA290673
Award Date
8/1/24
Completion Date
7/31/29
Dollars Obligated
$448K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Cooperative Agreement
Place of Performance
Anchorage, AK 99508, USA
Similar Awards
The National Cancer Institute awarded a $5,151,564 Project Grant under the Cancer Centers Support Grants (CFDA 93.397) program to the Fred Hutchinson Cancer Center in Seattle, Washington. The grant will fund a 5-year Translational Research Program focused on reducing colorectal cancer disparities, particularly among African American and Alaska Native populations. The program will conduct four translational research projects supported by cores in leadership, biospecimens, and biostatistics. Key...
The National Cancer Institute (NCI) has awarded a 5-year, $720,252 Cooperative Agreement under the Cancer Cause and Prevention Research (CFDA 93.393) program to the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, Massachusetts. The project, titled "Characterizing Genetic Risk of Cancer Across Diverse Populations Through Multi-Ancestry Epigenome Profiling and Chromatin QTL Discovery," aims to identify novel genetic variants associated with cancer risk in diverse ancestral...
The National Cancer Institute (NCI) of the National Institutes of Health (NIH) awarded a $622,913 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to the University of California, Los Angeles (UCLA). The grant, awarded on September 5, 2024, will fund a 5-year study to evaluate a multilevel intervention to increase colonoscopic follow-up rates after abnormal stool-based colorectal cancer screening tests among patients at federally qualified health centers...
This $498,309 Project Grant award from the National Institute on Minority Health and Health Disparities (CFDA 93.307 - Minority Health and Health Disparities Research) supports research to identify unique biological factors associated with colorectal cancer among Native Hawaiians. Key objectives include utilizing whole exome DNA sequencing to validate genetic mutations, profiling metabolomic features, and validating ethnic-specific genetic and metabolomic factors that influence colorectal cancer...
This federal Project Grant award from the National Cancer Institute (NCI), under the CFDA 93.393 Cancer Cause and Prevention Research program, provides $399,187 to Virginia Commonwealth University (VCU) to investigate the role of ATG16L1 isoforms in colorectal cancer health disparities. The research aims to determine whether the ATG16L1 T300T isoform is a prognostic indicator of response and a predictive treatment biomarker for African American colorectal cancer patients. The project will use...
This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Cause and Prevention Research program (CFDA 93.393), provides $2,136,715.00 to Harvard College President & Fellows Of, specifically its Harvard T.H. Chan School of Public Health division. The award, effective August 1, 2024, aims to harness DNA methylation in peripheral blood for improved colorectal cancer prevention. The project will involve collaborations with Dana-Farber Cancer Institute and Boston...
This $1,793,830 federal Project Grant award was granted by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393). The primary recipient, the University of Kansas Medical Center Research Institute, Inc. (KUMCRI), will conduct a cluster-randomized trial across 20 primary care clinics serving communities with at least 25% Spanish-speaking patient populations. The study aims to compare the impact of a Normalization Process Theory-guided...
The U.S. National Cancer Institute (NCI) awarded a $2,514,759 Cooperative Agreement under the federal Cancer Cause and Prevention Research (CFDA 93.393) program to The Regents of the University of California, San Francisco (UCSF) on July 8, 2024. This grant supports the establishment of the ASPIRE (Asian American Prospective Research Cohort) study, a 20,000-participant, community-engaged cohort focused on investigating multi-level determinants of cancer risk and etiology in diverse Asian...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research program) totaling $224,099 will support research at the University of California, San Diego (UCSD) to develop a targeted colorectal cancer (CRC) screening strategy for adults aged 45-49. The key objectives are to: Characterize the acceptability of CRC screening in this age group through a pilot trial and surveys/interviews to identify effective implementation strategies. Conduct a...
This Project Grant award, with a total funding amount of $456,764.00 and an award date of December 13, 2024, was provided by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) federal grant program. The objective of this research project is to study differences in bile acid metabolism and colonic responses between African Americans and non-Hispanic whites, in order to elucidate potential connections to colorectal cancer risk and disparities. The...